Long-term nonsurgical management of Barrett's esophagus with high-grade dysplasia.

Impact of endoscopic surveillance on mortality from Barrett's esophagus-associated esophageal adenocarcinomas. Gastroenterology (2013) 4.43

Durability of radiofrequency ablation in Barrett's esophagus with dysplasia. Gastroenterology (2011) 3.44

Barrett's oesophagus and oesophageal adenocarcinoma: time for a new synthesis. Nat Rev Cancer (2010) 3.27

Long-term survival following endoscopic and surgical treatment of high-grade dysplasia in Barrett's esophagus. Gastroenterology (2007) 2.86

American Gastroenterological Association technical review on the management of Barrett's esophagus. Gastroenterology (2011) 2.50

Extent of high-grade dysplasia in Barrett's esophagus correlates with risk of adenocarcinoma. Gastroenterology (2001) 2.30

Plasma ghrelin following cure of Helicobacter pylori. Gut (2003) 2.20

A cost-utility analysis of ablative therapy for Barrett's esophagus. Gastroenterology (2009) 1.95

Utility of biomarkers in prediction of response to ablative therapy in Barrett's esophagus. Gastroenterology (2008) 1.87

Elastic scattering spectroscopy accurately detects high grade dysplasia and cancer in Barrett's oesophagus. Gut (2006) 1.78

The cost effectiveness of radiofrequency ablation for Barrett's esophagus. Gastroenterology (2012) 1.65

High-grade dysplasia in Barrett's oesophagus. The case against oesophageal resection. Ann R Coll Surg Engl (2007) 1.47

Predictors of progression in Barrett's esophagus: current knowledge and future directions. Am J Gastroenterol (2010) 1.35

MicroRNA expression signatures in Barrett's esophagus and esophageal adenocarcinoma. Clin Cancer Res (2009) 1.35

Temporal and spatial evolution of somatic chromosomal alterations: a case-cohort study of Barrett's esophagus. Cancer Prev Res (Phila) (2013) 1.31

What is the best management strategy for high grade dysplasia in Barrett's oesophagus? A cost effectiveness analysis. Gut (2004) 1.29

Barrett's oesophagus: from metaplasia to dysplasia and cancer. Gut (2005) 1.18

MicroRNA expression signatures during malignant progression from Barrett's esophagus to esophageal adenocarcinoma. Cancer Prev Res (Phila) (2013) 1.18

Chromosomal instability and copy number alterations in Barrett's esophagus and esophageal adenocarcinoma. Clin Cancer Res (2009) 1.17

Genome-wide catalogue of chromosomal aberrations in barrett's esophagus and esophageal adenocarcinoma: a high-density single nucleotide polymorphism array analysis. Cancer Prev Res (Phila) (2010) 1.12

Barrett's esophagus and the increasing role of endoluminal therapy. Therap Adv Gastroenterol (2008) 1.11

Endoscopic mucosal resection for high-grade dysplasia and intramucosal carcinoma in Barrett's esophagus: an Italian experience. World J Gastroenterol (2005) 1.10

DNA promoter hypermethylation of p16 and APC predicts neoplastic progression in Barrett's esophagus. Am J Gastroenterol (2009) 1.08

Clinical and pathologic response of Barrett's esophagus to laparoscopic antireflux surgery. Ann Surg (2003) 1.08

Cost-effectiveness of photodynamic therapy for treatment of Barrett's esophagus with high grade dysplasia. Dig Dis Sci (2003) 1.07

Minichromosome maintenance (MCM) proteins may be pre-cancer markers. Gut (2002) 1.07

Epidemiology and biology of esophageal cancer. Gastrointest Cancer Res (2009) 1.04

Barrett's esophagus: Incidence, etiology, pathophysiology, prevention and treatment. Ther Clin Risk Manag (2007) 1.00

Biomarkers in Barrett's esophagus and esophageal adenocarcinoma: predictors of progression and prognosis. World J Gastroenterol (2010) 0.98

Are screening and surveillance for Barrett's oesophagus really worthwhile? Gut (2005) 0.97

Predictive factors of coexisting cancer in Barrett's high-grade dysplasia. Surg Endosc (2006) 0.96

Barrett esophagus: histology and pathology for the clinician. Nat Rev Gastroenterol Hepatol (2009) 0.95

Natural history of Barrett's esophagus. World J Gastroenterol (2012) 0.93

Approach to early Barrett's cancer. World J Surg (2003) 0.93

Barrett's esophagus: endoscopic treatments II. Ann N Y Acad Sci (2011) 0.92

Effects of Nissen fundoplication on endoscopic endoluminal radiofrequency ablation of Barrett's esophagus. Surg Endosc (2010) 0.91

Photodynamic therapy vs radiofrequency ablation for Barrett's dysplasia: efficacy, safety and cost-comparison. World J Gastroenterol (2013) 0.89

Antagonist: endoscopic surveillance of patients with Barrett's oesophagus. Gut (2002) 0.89

Can extent of high grade dysplasia in Barrett's oesophagus predict the presence of adenocarcinoma at oesophagectomy? Gut (2003) 0.89

Endoscopic mucosal resection of large hyperplastic polyps in 3 patients with Barrett's esophagus. World J Gastroenterol (2006) 0.88

Surveillance in Barrett's esophagus: an audit of practice. Dig Dis Sci (2009) 0.88

Comparison of nuclear texture analysis and image cytometric DNA analysis for the assessment of dysplasia in Barrett's oesophagus. Br J Cancer (2011) 0.88

Barrett's esophagus and its correlation with gastroesophageal reflux in Chinese. World J Gastroenterol (2004) 0.86

Photodynamic therapy for Barrett's esophagus with high-grade dysplasia: a cost-effectiveness analysis. Can J Gastroenterol (2007) 0.86

Correlation of histology with biomarker status after photodynamic therapy in Barrett esophagus. Cancer (2008) 0.86

Emerging aspects of oesophageal and gastro-oesophageal junction cancer histopathology - an update for the surgical oncologist. World J Surg Oncol (2006) 0.86

Patient preferences for the management of high-grade dysplasia in Barrett's esophagus. Dig Dis Sci (2005) 0.85

Zoning of mucosal phenotype, dysplasia, and telomerase activity measured by telomerase repeat assay protocol in Barrett's esophagus. Neoplasia (2004) 0.85

Distinction between short-segment Barrett's esophageal and cardiac intestinal metaplasia. World J Gastroenterol (2005) 0.85

Barrett's oesophagus: an ideal model to study cancer genetics. Hum Genet (2009) 0.84

Optimal conditions for successful ablation of high-grade dysplasia in Barrett's oesophagus using aminolaevulinic acid photodynamic therapy. Lasers Med Sci (2008) 0.84

Quality of life in patients with various Barrett's esophagus associated health states. Health Qual Life Outcomes (2006) 0.84

How light dosimetry influences the efficacy of photodynamic therapy with 5-aminolaevulinic acid for ablation of high-grade dysplasia in Barrett's esophagus. Lasers Med Sci (2007) 0.83

Early events during neoplastic progression in Barrett's esophagus. Cancer Biomark (2010) 0.83

Endoscopic Resection with Ligation Using a Multi-Band Mucosectomy System in Barrett's Esophagus with High-Grade Dysplasia and Intramucosal Carcinoma. Therap Adv Gastroenterol (2009) 0.82

Barrett's esophagus with high-grade dysplasia: focus on current treatment options. World J Gastroenterol (2011) 0.82

Prophylactic esophagectomy in Barrett esophagus with high-grade dysplasia. Langenbecks Arch Surg (2003) 0.82

Molecular imaging for guiding oncologic prognosis and therapy in esophageal adenocarcinoma. Hosp Pract (1995) (2011) 0.82

Endoscopic therapy for Barrett's oesophagus. Gut (2005) 0.82

Disputing dysplasia. Gastroenterology (2001) 0.82

Magnitude of Missed Esophageal Adenocarcinoma After Barrett's Esophagus Diagnosis: A Systematic Review and Meta-analysis. Gastroenterology (2015) 0.81

Correlation of the presence and extent of loss of heterozygosity mutations with histological classifications of Barrett's esophagus. BMC Gastroenterol (2012) 0.81

Genetic Insights in Barrett's Esophagus and Esophageal Adenocarcinoma. Gastroenterology (2015) 0.81

Differences in genetic instability and cellular phenotype among Barrett's, cardiac, and gastric intestinal metaplasia in a Japanese population with Helicobacter pylori. Histopathology (2009) 0.80

Barrett's Esophagus: Diagnosis, Screening, Surveillance, and Controversies. Gut Liver (2007) 0.80

Assessment of mutational load in biopsy tissue provides additional information about genomic instability to histological classifications of Barrett's esophagus. J Gastrointest Cancer (2014) 0.79

Ablative mucosectomy is the procedure of choice to prevent Barrett's cancer. Gut (2003) 0.79

Epidemiology of Barrett's Esophagus and Esophageal Adenocarcinoma. Gastroenterol Clin North Am (2015) 0.79

Minimally invasive esophagectomy for Barrett's with high-grade dysplasia and early adenocarcinoma of the esophagus. J Gastrointest Surg (2010) 0.79

Barrett's Esophagus: Emerging Knowledge and Management Strategies. Patholog Res Int (2012) 0.78

Predictive biomarkers for Barrett's esophagus: so near and yet so far. Dis Esophagus (2013) 0.78

Molecular changes in the progression of Barrett's oesophagus. Postgrad Med J (2007) 0.78

Diagnosis and management of Barrett's esophagus for the endoscopist. Therap Adv Gastroenterol (2010) 0.78

Barrett's esophagus and neoplasia: data from the Bayreuth Barrett's archive. Gastroenterology (2002) 0.78

Diagnosis and management of Barrett's esophagus. Surg Clin North Am (2012) 0.78

Prevention of adenocarcinoma by reversing Barrett's esophagus with mucosal ablation. World J Surg (2003) 0.78

CAGS and ACS evidence based reviews in surgery. Guidelines for the management of Barrett esophagus with high-grade dysplasia? Can J Surg (2011) 0.78

Endoscopic management of Barrett's esophagus: advances in endoscopic techniques. Dig Dis Sci (2012) 0.78

Observer variation in the diagnosis of superficial oesophageal adenocarcinoma: another spanner in the works? Gut (2002) 0.77

Evaluation of fatty acid synthase expression in oesophageal mucosa of patients with oesophagitis, Barrett's oesophagus and adenocarcinoma. J Cancer Res Clin Oncol (2009) 0.77

Low risk of prevalent submucosal invasive cancer among patients undergoing esophagectomy for treatment of Barrett's esophagus with high grade dysplasia. J Gastrointest Oncol (2011) 0.77

Photodynamic therapy in Barrett's esophagus: results of treatment of 17 patients. Can J Gastroenterol (2006) 0.77

Statins and aspirin for chemoprevention in Barrett's esophagus: results of a cost-effectiveness analysis. Cancer Prev Res (Phila) (2013) 0.77

Drinking from the fountain of promise: biomarkers in the surveillance of Barrett's oesophagus--the glass is half full! Gut (2006) 0.77

Management of Barrett's oesophagus and intramucosal oesophageal cancer: a review of recent development. Therap Adv Gastroenterol (2012) 0.76

Barrett's oesophagus and adenocarcinoma. World J Surg Oncol (2004) 0.76

A laparoscopic vagus-preserving Merendino procedure for early esophageal adenocarcinoma. Surg Endosc (2009) 0.75

Surveillance in Barrett's oesophagus: a personal view. Postgrad Med J (2002) 0.75

Medical and endoscopic management of high-grade dysplasia in Barrett's esophagus. Dis Esophagus (2012) 0.75

Endoluminal Therapies for Barrett's Esophagus and Dysplasia. Gastroenterol Hepatol (N Y) (2006) 0.75

Clinical and psychosocial variables associated with behavioral intentions to undergo surveillance endoscopy. BMC Gastroenterol (2014) 0.75

Surrogate Markers: Lessons from the Next Gen? Cancer Prev Res (Phila) (2016) 0.75

[Barrett's esophagus. An update]. Pathologe (2012) 0.75

Endoscopic mucosal resection for high-grade dysplasia and intramucosal carcinoma: a Canadian experience. Can J Surg (2017) 0.75

Surveillance in Barrett esophagus. J Med Life (2014) 0.75

Endoscopic ablation is a cost-effective cancer preventative therapy in patients with Barrett's esophagus who have elevated genomic instability. Endosc Int Open (2016) 0.75

Biomarkers in the molecular pathogenesis of esophageal (Barrett) adenocarcinoma. Curr Oncol (2006) 0.75

Recent developments in pathogenesis, diagnosis and therapy of Barrett's esophagus. World J Gastroenterol (2015) 0.75

Low prevalence of invasive adenocarcinoma and occult cancer on esophageal resection for Barrett's esophagus with high-grade dysplasia: Evidence for conservative management. J Gastrointest Oncol (2011) 0.75

[Intraepithelial neoplasia of Barrett's esophagus: prognosis of potential malignancy]. Pathologe (2011) 0.75

Use of colonoscopy to screen asymptomatic adults for colorectal cancer. Veterans Affairs Cooperative Study Group 380. N Engl J Med (2000) 13.21

Protection by endoscopy against death from colorectal cancer. A case-control study among veterans. Arch Intern Med (1995) 5.59

Colorectal cancer prevention 2000: screening recommendations of the American College of Gastroenterology. American College of Gastroenterology. Am J Gastroenterol (2000) 4.17

Function and interactions of integrins. Cell Tissue Res (2001) 4.13

Survival and causes of death in cirrhotic and in noncirrhotic patients with primary hemochromatosis. N Engl J Med (1985) 3.73

Prevention of colorectal cancer by flexible endoscopy and polypectomy. A case-control study of 32,702 veterans. Ann Intern Med (1995) 3.54

Epithelial detachment due to absence of hemidesmosomes in integrin beta 4 null mice. Nat Genet (1996) 3.52

Helicobacter-negative gastritis: a distinct entity unrelated to Helicobacter pylori infection. Aliment Pharmacol Ther (2014) 3.38

The prevalence of hemorrhoids and chronic constipation. An epidemiologic study. Gastroenterology (1990) 3.22

The alpha 1/beta 1 and alpha 6/beta 1 integrin heterodimers mediate cell attachment to distinct sites on laminin. J Cell Biol (1990) 3.07

A complex of platelet glycoproteins Ic and IIa identified by a rat monoclonal antibody. J Biol Chem (1987) 2.94

Structural and functional aspects of filamins. Biochim Biophys Acta (2001) 2.89

Pitx2 regulates lung asymmetry, cardiac positioning and pituitary and tooth morphogenesis. Nature (1999) 2.64

Structure and function of hemidesmosomes: more than simple adhesion complexes. J Invest Dermatol (1999) 2.64

Management of weight problems and obesity: knowledge, attitudes and current practice of general practitioners. Br J Gen Pract (1991) 2.47

Episialin (MUC1) overexpression inhibits integrin-mediated cell adhesion to extracellular matrix components. J Cell Biol (1995) 2.41

Sporadic acute hepatitis E in the united kingdom: an underdiagnosed phenomenon? Gut (2000) 2.38

Most asthmatics have gastroesophageal reflux with or without bronchodilator therapy. Gastroenterology (1990) 2.37

Association of the VLA alpha 6 subunit with a novel protein. A possible alternative to the common VLA beta 1 subunit on certain cell lines. J Biol Chem (1989) 2.34

Mouse egg integrin alpha 6 beta 1 functions as a sperm receptor. Cell (1995) 2.32

Cloning and sequence analysis of beta-4 cDNA: an integrin subunit that contains a unique 118 kd cytoplasmic domain. EMBO J (1990) 2.23

Lyme borreliosis: clinical case definitions for diagnosis and management in Europe. Clin Microbiol Infect (2011) 2.23

Multiple very late antigen (VLA) heterodimers on platelets. Evidence for distinct VLA-2, VLA-5 (fibronectin receptor), and VLA-6 structures. J Biol Chem (1988) 2.20

AGA technical review: evaluation of dyspepsia. American Gastroenterological Association. Gastroenterology (1998) 2.19

Monoclonal antibodies against human milk-fat globule membranes detecting differentiation antigens of the mammary gland and its tumors. Int J Cancer (1984) 2.12

Pancreatitis is a risk factor for pancreatic cancer. Gastroenterology (1995) 2.11

Identification of a seven transmembrane helix receptor for corticotropin-releasing factor and sauvagine in mammalian brain. Neuron (1993) 2.10

Temporal changes in the occurrence of hemorrhoids in the United States and England. Dis Colon Rectum (1991) 2.09

Tst-1/Oct-6/SCIP regulates a unique step in peripheral myelination and is required for normal respiration. Genes Dev (1996) 2.02

The tetraspan molecule CD151, a novel constituent of hemidesmosomes, associates with the integrin alpha6beta4 and may regulate the spatial organization of hemidesmosomes. J Cell Biol (2000) 2.00

Gastric surgery is not a risk for Barrett's esophagus or esophageal adenocarcinoma. Gastroenterology (2001) 1.99

Opposing time trends of peptic ulcer and reflux disease. Gut (1998) 1.99

Cholecystectomy in cirrhotic patients: a formidable operation. Am J Surg (1982) 1.90

Analysis of the tumor-associated antigen TSP-180. Identity with alpha 6-beta 4 in the integrin superfamily. J Biol Chem (1989) 1.88

Clinical epidemiology of chronic constipation. J Clin Gastroenterol (1989) 1.85

Recognition of the laminin E8 cell-binding site by an integrin possessing the alpha 6 subunit is essential for epithelial polarization in developing kidney tubules. J Cell Biol (1990) 1.85

Brn-3.0: a POU-domain protein expressed in the sensory, immune, and endocrine systems that functions on elements distinct from known octamer motifs. Proc Natl Acad Sci U S A (1993) 1.79

Predictors of duodenal ulcer healing and relapse. Gastroenterology (1981) 1.78

The importance of hiatal hernia in reflux esophagitis compared with lower esophageal sphincter pressure or smoking. J Clin Gastroenterol (1991) 1.77

Effect of early intervention with sumatriptan on migraine pain: retrospective analyses of data from three clinical trials. Clin Ther (2000) 1.76

Diagnosis and management of colorectal cancer: summary of NICE guidance. BMJ (2011) 1.76

Adenocarcinomas arising in tongues or short segments of Barrett's esophagus. Dig Dis Sci (1992) 1.71

Expression and reconstitution of a biologically active human interferon-gamma receptor in hamster cells. J Biol Chem (1990) 1.70

Transfection of the int-1 mammary oncogene in cuboidal RAC mammary cell line results in morphological transformation and tumorigenicity. EMBO J (1987) 1.69

The alpha 6 beta 4 integrin is a receptor for both laminin and kalinin. Exp Cell Res (1994) 1.69

Epidemiology and practice patterns of achalasia in a large multi-centre database. Aliment Pharmacol Ther (2011) 1.67

Comorbid occurrence of laryngeal or pulmonary disease with esophagitis in United States military veterans. Gastroenterology (1997) 1.66

Induction of cell scattering by expression of beta1 integrins in beta1-deficient epithelial cells requires activation of members of the rho family of GTPases and downregulation of cadherin and catenin function. J Cell Biol (1999) 1.64

Binding of integrin alpha6beta4 to plectin prevents plectin association with F-actin but does not interfere with intermediate filament binding. J Cell Biol (1999) 1.64

Hedgehog signaling is required for pituitary gland development. Development (2001) 1.62

Development of mouse mammary gland: identification of stages in differentiation of luminal and myoepithelial cells using monoclonal antibodies and polyvalent antiserum against keratin. J Histochem Cytochem (1986) 1.61

Hemidesmosome formation is initiated by the beta4 integrin subunit, requires complex formation of beta4 and HD1/plectin, and involves a direct interaction between beta4 and the bullous pemphigoid antigen 180. J Cell Biol (1998) 1.58

Distinct and overlapping ligand specificities of the alpha 3A beta 1 and alpha 6A beta 1 integrins: recognition of laminin isoforms. Mol Biol Cell (1994) 1.56

Hemidesmosomes: roles in adhesion, signaling and human diseases. Curr Opin Cell Biol (1996) 1.56

Efficient management of diarrhea in the acquired immunodeficiency syndrome (AIDS). A medical decision analysis. Ann Intern Med (1990) 1.55

Biology and function of hemidesmosomes. Matrix Biol (1999) 1.51

European Union Concerted Action on Risk Assessment in Lyme Borreliosis: clinical case definitions for Lyme borreliosis. Wien Klin Wochenschr (1996) 1.51

Comparing lansoprazole and omeprazole in onset of heartburn relief: results of a randomized, controlled trial in erosive esophagitis patients. Am J Gastroenterol (2001) 1.50

Fecal occult blood screening for colorectal cancer in a Veterans Administration Hospital. Am J Surg (1983) 1.47

Integrin binding specificity of laminin-10/11: laminin-10/11 are recognized by alpha 3 beta 1, alpha 6 beta 1 and alpha 6 beta 4 integrins. J Cell Sci (2000) 1.46

Geographic and temporal variations in the occurrence of peptic ulcer disease. Scand J Gastroenterol Suppl (1985) 1.45

Ethnic variations in the occurrence of gastroesophageal cancers. J Clin Gastroenterol (1999) 1.43

The value of serological testing for Lyme disease in the UK. Br J Rheumatol (1995) 1.43

Military history of patients with inflammatory bowel disease: an epidemiological study among U.S. veterans. Am J Gastroenterol (1998) 1.42

Limitations of the faecal occult blood test in screening for colorectal cancer. Ital J Gastroenterol Hepatol (1999) 1.42

P-selectin mediates Ca(2+)-dependent adhesion of activated platelets to many different types of leukocytes: detection by flow cytometry. Blood (1992) 1.41

Role of binding of plectin to the integrin beta4 subunit in the assembly of hemidesmosomes. Mol Biol Cell (2003) 1.41

AHPBA/AJCC consensus conference on staging of hepatocellular carcinoma: consensus statement. HPB (Oxford) (2003) 1.39

Epithelial development and differentiation in the mammary gland is not dependent on alpha 3 or alpha 6 integrin subunits. Dev Biol (2001) 1.38

Molecular cloning of the human alpha 6 integrin subunit. Alternative splicing of alpha 6 mRNA and chromosomal localization of the alpha 6 and beta 4 genes. Eur J Biochem (1991) 1.38

Analysis of a flawed double-blind, placebo-controlled, clinical trial of patients claimed to have persistent Lyme disease following treatment. Minerva Med (2009) 1.38

Deficiency of the integrin beta 4 subunit in junctional epidermolysis bullosa with pyloric atresia: consequences for hemidesmosome formation and adhesion properties. J Cell Sci (1996) 1.37

Biochemical characterization and tissue distribution of the A and B variants of the integrin alpha 6 subunit. J Cell Biol (1993) 1.34

GP non-principals' education: let's improve access for our flexible friends. Br J Gen Pract (1998) 1.31

Correlation of inflammatory infiltrate with the enlargement of experimental aortic aneurysms. J Vasc Surg (1992) 1.29

Bupropion SR as an aid to smoking cessation in smokers treated previously with bupropion: a randomized placebo-controlled study. Clin Pharmacol Ther (2001) 1.29

Barrett's oesophagus and colonic tumours. Lancet (1985) 1.28

The LIM-only protein DRAL/FHL2 binds to the cytoplasmic domain of several alpha and beta integrin chains and is recruited to adhesion complexes. J Biol Chem (2000) 1.27

Skeletal myoblasts utilize a novel beta 1-series integrin and not alpha 6 beta 1 for binding to the E8 and T8 fragments of laminin. J Biol Chem (1991) 1.26

Identification of the Arg-Gly-Asp sequence in laminin A chain as a latent cell-binding site being exposed in fragment P1. FEBS Lett (1990) 1.26

Novel approach to quantify duodenogastric reflux in healthy volunteers and in patients with type I gastric ulcer. Gut (1983) 1.25

Glycoproteins V and Ib-IX form a noncovalent complex in the platelet membrane. J Biol Chem (1992) 1.24

Integrins: alternative splicing as a mechanism to regulate ligand binding and integrin signaling events. Bioessays (1999) 1.24

alpha3beta1 and alpha6beta4 integrin receptors for laminin-5 are not essential for epidermal morphogenesis and homeostasis during skin development. J Cell Sci (2000) 1.23

Cre-loxP-mediated inactivation of the alpha6A integrin splice variant in vivo: evidence for a specific functional role of alpha6A in lymphocyte migration but not in heart development. J Cell Biol (1998) 1.23

Gastroesophageal reflux disease is a risk factor for laryngeal and pharyngeal cancer. Am J Gastroenterol (2001) 1.23

Corpus gastritis is protective against reflux oesophagitis. Gut (1999) 1.23

Antibody to integrin alpha 6 subunit specifically inhibits cell-binding to laminin fragment 8. Exp Cell Res (1990) 1.21

Pax6 is essential for establishing ventral-dorsal cell boundaries in pituitary gland development. Proc Natl Acad Sci U S A (1999) 1.21

Associations between different forms of gastro-oesophageal reflux disease. Gut (1997) 1.21

Expression and function of the cytoplasmic variants of the integrin alpha 6 subunit in transfected K562 cells. Activation-dependent adhesion and interaction with isoforms of laminin. J Biol Chem (1993) 1.20

Step-down management of gastroesophageal reflux disease. Gastroenterology (2001) 1.20

When is esophagitis healed? esophageal endoscopy, histology and function before and after cimetidine treatment. Dig Dis Sci (1982) 1.20